drugset / Trial / NCT01091220

Evaluation of the Effects of Certolizumab Pegol on Semen Quality in Healthy Male Volunteers

NCT01091220

Phase 1 Completed 20 enrolled UCB Pharma
RandomizedParallel-groupDouble-blind

Summary

The primary objective of this study is to evaluate the effect of certolizumab pegol (CZP) on the quality of sperm obtained from healthy male volunteers.

Timeline

Start
2010-03
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Certolizumab Pegol Protein / enzyme biologic 400 mg Subcutaneous

Indications